Martin Metz Selected Research

Martin Metz Research Topics

Disease

32	Chronic Urticaria 01/2022 - 07/2009
18	Pruritus (Itching) 02/2022 - 01/2010
18	Urticaria (Hives) 12/2021 - 01/2010
16	Inflammation (Inflammations) 01/2020 - 09/2006
11	Hypersensitivity (Allergy) 01/2021 - 08/2003
9	Anaphylaxis (Anaphylactic Shock) 03/2020 - 12/2006
7	Prurigo 01/2022 - 03/2013
7	Cold Urticaria 12/2021 - 01/2010
7	Contact Dermatitis (Eczema, Contact) 01/2019 - 08/2003
6	Angioedema 01/2021 - 12/2015
5	Atopic Dermatitis (Atopic Eczema) 02/2022 - 10/2012
4	Asthma (Bronchial Asthma) 01/2020 - 12/2009
4	Familial dermographism 01/2018 - 01/2011
3	Solar Urticaria 01/2018 - 01/2011
3	Chronic Inducible Urticaria 01/2018 - 01/2014
3	Infections 04/2012 - 06/2007
3	Sepsis (Septicemia) 01/2011 - 08/2007
2	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 07/2021
2	Neoplasms (Cancer) 12/2021 - 03/2014
2	Skin Diseases (Skin Disease) 01/2021 - 12/2016
2	Hereditary Angioedemas 01/2020 - 04/2010
2	Wounds and Injuries (Trauma) 10/2019 - 03/2013
2	Necrosis 01/2017 - 01/2012
2	Bacterial Infections (Bacterial Infection) 01/2011 - 12/2009
2	Peritonitis 01/2011 - 08/2007
2	Immediate Hypersensitivity 12/2009 - 12/2006
1	Pain (Aches) 01/2021
1	Drug Hypersensitivity (Drug Allergy) 01/2021
1	COVID-19 01/2021
1	Wells syndrome 07/2020
1	Hypereosinophilic Syndrome (Loeffler Endocarditis) 11/2019
1	Cicatrix (Scar) 10/2019
1	Parasitic Diseases (Parasitic Disease) 10/2019

Drug/Important Bio-Agent (IBA)

22	Omalizumab (Xolair)FDA Link 01/2022 - 09/2010
15	Immunoglobulin E (IgE)IBA 01/2022 - 12/2006
9	Histamine (Histamine Dihydrochloride)FDA Link 02/2022 - 10/2009
8	Histamine Antagonists (Antihistamines)IBA 01/2022 - 01/2011
8	AllergensIBA 12/2021 - 08/2003
6	CytokinesIBA 02/2022 - 06/2007
5	Pharmaceutical PreparationsIBA 01/2021 - 08/2012
5	Substance PIBA 01/2021 - 04/2011
5	AntigensIBA 03/2020 - 12/2006
5	AntipruriticsIBA 04/2019 - 09/2013
4	Cholinergic Agents (Cholinergics)IBA 01/2020 - 03/2014
4	anti-IgE antibodiesIBA 01/2019 - 01/2014
4	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 08/2007
3	ligelizumabIBA 01/2022 - 10/2019
3	Immunoglobulin G (IgG)IBA 01/2022 - 07/2021
3	NeuropeptidesIBA 01/2022 - 04/2008
3	AutoantibodiesIBA 11/2021 - 04/2011
3	AntibodiesIBA 07/2021 - 11/2013
3	VenomsIBA 03/2020 - 11/2013
3	BradykininIBA 01/2020 - 04/2010
3	Tryptases (Tryptase)IBA 10/2019 - 10/2009
3	rupatadineIBA 12/2015 - 01/2010
3	Chymases (Chymase)IBA 02/2014 - 08/2007
3	Interleukin-6 (Interleukin 6)IBA 02/2014 - 01/2012
3	Interleukin-10 (Interleukin 10)IBA 01/2012 - 08/2003
2	Interleukin-13IBA 02/2022 - 02/2014
2	Interleukin-4 (Interleukin 4)IBA 02/2022 - 01/2012
2	Iodide Peroxidase (Deiodinase)IBA 01/2022 - 04/2011
2	dupilumabIBA 09/2021 - 01/2019
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021 - 01/2021
2	mepolizumabIBA 07/2020 - 04/2018
2	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2019 - 05/2009
2	Aprepitant (Emend)FDA Link 04/2019 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 02/2014
2	canakinumab FDA Link 04/2017 - 09/2013
2	mast cell protease 4IBA 02/2014 - 03/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 03/2013
2	Thymic Stromal LymphopoietinIBA 04/2012 - 12/2009
2	Peptides (Polypeptides)IBA 05/2009 - 04/2008
2	Bacterial ToxinsIBA 05/2009 - 02/2009
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022
1	cortistatinIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	GSK2646264IBA 12/2021
1	Syk KinaseIBA 12/2021
1	enfortumab vedotinIBA 12/2021
1	fenebrutinibIBA 11/2021
1	Agammaglobulinaemia Tyrosine KinaseIBA 11/2021
1	baricitinibIBA 09/2021
1	Antinuclear AntibodiesIBA 07/2021
1	Immunoglobulin A (IgA)IBA 01/2021
1	Peroxidase (Myeloperoxidase)IBA 01/2021
1	LigandsIBA 01/2021
1	Eosinophil Major Basic ProteinIBA 01/2021
1	Biological ProductsIBA 01/2020
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2020
1	Neutralizing AntibodiesIBA 01/2020
1	reslizumabIBA 11/2019
1	Leukotriene Antagonists (Leukotriene Receptor Antagonists)IBA 10/2019
1	CathelicidinsIBA 10/2019
1	Codeine (Codeine Phosphate)FDA LinkGeneric 07/2019

Therapy/Procedure

23	Therapeutics 01/2022 - 09/2010
3	Injections 01/2014 - 09/2006
3	Punctures 01/2011 - 08/2007
3	Ligation 01/2011 - 08/2007
1	Biological Therapy 01/2021
1	Self Administration (Administration, Self) 01/2021